These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 21304219)

  • 1. Comparison of immunosorbent assays for the quantification of biomarkers for Alzheimer's disease in human cerebrospinal fluid.
    Schipke CG; Prokop S; Heppner FL; Heuser I; Peters O
    Dement Geriatr Cogn Disord; 2011; 31(2):139-45. PubMed ID: 21304219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebrospinal fluid tau, p-tau 181 and amyloid-β38/40/42 in frontotemporal dementias and primary progressive aphasias.
    Bibl M; Mollenhauer B; Lewczuk P; Esselmann H; Wolf S; Otto M; Kornhuber J; Rüther E; Wiltfang J
    Dement Geriatr Cogn Disord; 2011; 31(1):37-44. PubMed ID: 21135556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebrospinal fluid markers for Alzheimer's disease in a cognitively healthy cohort of young and old adults.
    Paternicò D; Galluzzi S; Drago V; Bocchio-Chiavetto L; Zanardini R; Pedrini L; Baronio M; Amicucci G; Frisoni GB
    Alzheimers Dement; 2012 Nov; 8(6):520-7. PubMed ID: 22677492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma beta carotene in Alzheimer's disease. Association with cerebrospinal fluid beta-amyloid 1-40, (Abeta40), beta-amyloid 1-42 (Abeta42) and total Tau.
    Stuerenburg HJ; Ganzer S; Müller-Thomsen T
    Neuro Endocrinol Lett; 2005 Dec; 26(6):696-8. PubMed ID: 16380679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerebrospinal fluid biomarkers for Alzheimer's disease: more to come?
    Zetterberg H; Blennow K
    J Alzheimers Dis; 2013; 33 Suppl 1():S361-9. PubMed ID: 22710917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlations between soluble α/β forms of amyloid precursor protein and Aβ38, 40, and 42 in human cerebrospinal fluid.
    Gabelle A; Roche S; Gény C; Bennys K; Labauge P; Tholance Y; Quadrio I; Tiers L; Gor B; Chaulet C; Vighetto A; Croisile B; Krolak-Salmon P; Touchon J; Perret-Liaudet A; Lehmann S
    Brain Res; 2010 Oct; 1357():175-83. PubMed ID: 20713025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebrospinal fluid biomarkers for Alzheimer's disease.
    Blennow K; Zetterberg H
    J Alzheimers Dis; 2009; 18(2):413-7. PubMed ID: 19661632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal stability of CSF biomarkers in Alzheimer's disease.
    Blennow K; Zetterberg H; Minthon L; Lannfelt L; Strid S; Annas P; Basun H; Andreasen N
    Neurosci Lett; 2007 May; 419(1):18-22. PubMed ID: 17482358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer's disease, mild cognitive impairment, and healthy controls.
    Sundelöf J; Sundström J; Hansson O; Eriksdotter-Jönhagen M; Giedraitis V; Larsson A; Degerman-Gunnarsson M; Ingelsson M; Minthon L; Blennow K; Kilander L; Basun H; Lannfelt L
    J Alzheimers Dis; 2010; 21(2):471-8. PubMed ID: 20555147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Batch prepared protein standards for cerebrospinal fluid (CSF) biomarkers for neurodegeneration.
    Petzold A; Verwey NA; van Uffelen K; Blankenstein MA; Teunissen C
    J Neurosci Methods; 2010 Nov; 193(2):296-9. PubMed ID: 20832428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of cerebrospinal fluid tau/beta-amyloid(42) ratio as diagnostic markers for Alzheimer disease.
    Smach MA; Charfeddine B; Ben Othman L; Lammouchi T; Dridi H; Nafati S; Ltaief A; Bennamou S; Limem K
    Eur Neurol; 2009; 62(6):349-55. PubMed ID: 19786779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Could clinical profile influence CSF biomarkers in early-onset Alzheimer disease?
    Koric L; Felician O; Guedj E; Hubert AM; Mancini J; Boucraut J; Ceccaldi M
    Alzheimer Dis Assoc Disord; 2010; 24(3):278-83. PubMed ID: 20473135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Biomarkers in spinal fluid of patients with dementia].
    Skogseth RE; Fladby T; Mulugeta E; Aarsland D
    Tidsskr Nor Laegeforen; 2011 Nov; 131(22):2235-8. PubMed ID: 22085948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cerebrospinal fluid tau and beta-amyloid in Alzheimer patients, disease controls and an age-matched random sample.
    Ibach B; Binder H; Dragon M; Poljansky S; Haen E; Schmitz E; Koch H; Putzhammer A; Kluenemann H; Wieland W; Hajak G
    Neurobiol Aging; 2006 Sep; 27(9):1202-11. PubMed ID: 16085339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative.
    Vanderstichele H; Bibl M; Engelborghs S; Le Bastard N; Lewczuk P; Molinuevo JL; Parnetti L; Perret-Liaudet A; Shaw LM; Teunissen C; Wouters D; Blennow K
    Alzheimers Dement; 2012 Jan; 8(1):65-73. PubMed ID: 22047631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomarker profiles and their relation to clinical variables in mild cognitive impairment.
    Schoonenboom SN; Visser PJ; Mulder C; Lindeboom J; Van Elk EJ; Van Kamp GJ; Scheltens PH
    Neurocase; 2005 Feb; 11(1):8-13. PubMed ID: 15804919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term stability of Alzheimer's disease biomarker proteins in cerebrospinal fluid.
    Schipke CG; Jessen F; Teipel S; Luckhaus C; Wiltfang J; Esselmann H; Frölich L; Maier W; Rüther E; Heppner FL; Prokop S; Heuser I; Peters O
    J Alzheimers Dis; 2011; 26(2):255-62. PubMed ID: 21606567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
    Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
    Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CSF levels of heart fatty acid binding protein are altered during early phases of Alzheimer's disease.
    Chiasserini D; Parnetti L; Andreasson U; Zetterberg H; Giannandrea D; Calabresi P; Blennow K
    J Alzheimers Dis; 2010; 22(4):1281-8. PubMed ID: 20930282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CSF markers in Alzheimer disease patients are not related to the different degree of cognitive impairment.
    Stefani A; Martorana A; Bernardini S; Panella M; Mercati F; Orlacchio A; Pierantozzi M
    J Neurol Sci; 2006 Dec; 251(1-2):124-8. PubMed ID: 17097109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.